Key result
Pharmacist-led audit and feedback cuts unreasonable GDMT omissions in ACS patients to 0%.
Why the study?
Implementation of strategies to improve adherence to guideline-directed medical therapy remains suboptimal in acute coronary syndrome, especially in developing countries.
Does a clinical pharmacist-led clinical audit and feedback program improve adherence to guideline-directed medical therapy in patients admitted with acute coronary syndrome?
Observational (n=1,072)
Does a clinical pharmacist-led clinical audit and feedback program improve adherence to guideline-directed medical therapy in patients admitted with acute coronary syndrome?
A clinical pharmacist-led monthly audit and feedback program significantly eliminated unreasonable omissions of guideline-directed medical therapy at discharge for patients with acute coronary syndrome.
May support pharmacist-led audits to reduce GDMT omissions in ACS; hypothesis-generating and requires RCTs for confirmation.
BACKGROUND: Despite global consensus on the management of acute coronary syndrome (ACS), implementation of strategies to improve adherence of guideline-directed medical therapy (GDMT) remains sub-optimal, especially in developing countries. Thus, we aimed to assess the effect of clinical pharmacist-led clinical audit to improve the compliance of discharge prescriptions in patients admitted with ACS. It is a prospective clinical audit of ACS patients which was carried out for 12 months. The discharge prescriptions were audited by clinical pharmacists for the appropriateness in the usage of statins, dual antiplatelet therapy (DAPT), beta-blockers, and angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin receptor blocker (ARB). A feedback report was presented every month to the cardiologists involved in the patient care, and the trend in the adherence to GDMT was analyzed over 12 months. RESULTS: The discharge prescriptions of 1072 ACS patients were audited for the justifiable and non-justifiable omissions of mandated drugs. The first-month audit revealed unreasonable omissions of DAPT, statin, ACE-I/ARB, and beta-blockers in 1%, 0%, 14%, and 11% respectively, which reduced to nil by the end of the 11th month of the audit-feedback program. This improvement remained unchanged until the end of the 12th month. CONCLUSIONS: The study revealed that periodic clinical audit significantly improves adherence to GDMT in patients admitted with ACS.
No takes yet. Share an insight, caveat, or question.
George et al. (2022) conducted an observational in acute coronary syndrome (n=1,072). clinical pharmacist-led clinical audit and feedback vs. baseline was evaluated on unreasonable omissions of mandated drugs (DAPT, statin, ACE-I/ARB, beta-blockers). A clinical pharmacist-led audit and feedback program reduced unreasonable omissions of guideline-directed medical therapy in ACS patients to 0% by the 11th month.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: